Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven R Schwid

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|November 13, 2009
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohortsConnie Marras, Anthony E Lang, Shirley W Eberly, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 21, 2006
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida, Steven R Schwid, William B White, et al.
Muscle & Nerve|September 1, 2010
Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann, Alec B O'Connor, Steven R Schwid, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, et al.
The Lancet. Neurology|September 16, 2008
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D Mikol, Frederik Barkhof, Peter Chang, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid, Janice Bausch, David Oakes, et al.
Archives of Neurology|April 17, 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild, Steven R Schwid, Kenneth Marek, et al.
Neurology|June 25, 2003
A randomized controlled study of the acute and chronic effects of cooling therapy for MSSteven R Schwid, Mary D Petrie, Ronald Murray, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Movement Disorders : Official Journal of the Movement Disorder Society|November 13, 2009
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohortsConnie Marras, Anthony E Lang, Shirley W Eberly, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 21, 2006
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagilineJ Antonelle deMarcaida, Steven R Schwid, William B White, et al.
Muscle & Nerve|September 1, 2010
Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann, Alec B O'Connor, Steven R Schwid, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, et al.
The Lancet. Neurology|September 16, 2008
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialDaniel D Mikol, Frederik Barkhof, Peter Chang, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid, Janice Bausch, David Oakes, et al.
Archives of Neurology|April 17, 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild, Steven R Schwid, Kenneth Marek, et al.
Neurology|June 25, 2003
A randomized controlled study of the acute and chronic effects of cooling therapy for MSSteven R Schwid, Mary D Petrie, Ronald Murray, et al.
Pageof 3